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Summary
Background The UK COVID-19 vaccination programme has prioritised vaccination of those at the highest risk of 
COVID-19 mortality and hospitalisation. The programme was rolled out in Scotland during winter 2020–21, when 
SARS-CoV-2 infection rates were at their highest since the pandemic started, despite social distancing measures 
being in place. We aimed to estimate the frequency of COVID-19 hospitalisation or death in people who received at 
least one vaccine dose and characterise these individuals.
Methods We conducted a prospective cohort study using the Early Pandemic Evaluation and Enhanced Surveillance of 
COVID-19 (EAVE II) national surveillance platform, which contained linked vaccination, primary care, RT-PCR 
testing, hospitalisation, and mortality records for 5·4 million people (around 99% of the population) in Scotland. 
Individuals were followed up from receiving their first dose of the BNT162b2 (Pfizer–BioNTech) or ChAdOx1 nCoV-19 
(Oxford–AstraZeneca) COVID-19 vaccines until admission to hospital for COVID-19, death, or the end of the study 
period on April 18, 2021. We used a time-dependent Poisson regression model to estimate rate ratios (RRs) for 
demographic and clinical factors associated with COVID-19 hospitalisation or death 14 days or more after the first 
vaccine dose, stratified by vaccine type.
Findings Between Dec 8, 2020, and April 18, 2021, 2 572 008 individuals received their first dose of vaccine—841 090 (32·7%) 
received BNT162b2 and 1 730 918 (67·3%) received ChAdOx1. 1196 (<0·1%) individuals were admitted to hospital or 
died due to COVID-19 illness (883 hospitalised, of whom 228 died, and 313 who died due to COVID-19 without 
hospitalisation) 14 days or more after their first vaccine dose. These severe COVID-19 outcomes were associated with 
older age (≥80 years vs 18–64 years adjusted RR 4·75, 95% CI 3·85–5·87), comorbidities (five or more risk groups vs less 
than five risk groups 4·24, 3·34–5·39), hospitalisation in the previous 4 weeks (3·00, 2·47–3·65), high-risk occupations 
(ten or more previous COVID-19 tests vs less than ten previous COVID-19 tests 2·14, 1·62–2·81), care home residence 
(1·63, 1·32–2·02), socioeconomic deprivation (most deprived quintile vs least deprived quintile 1·57, 1·30–1·90), being 
male (1·27, 1·13–1·43), and being an ex-smoker (ex-smoker vs non-smoker 1·18, 1·01–1·38). A history of COVID-19 
before vaccination was protective (0·40, 0·29–0·54).
Interpretation COVID-19 hospitalisations and deaths were uncommon 14 days or more after the first vaccine dose in 
this national analysis in the context of a high background incidence of SARS-CoV-2 infection and with extensive social 
distancing measures in place. Sociodemographic and clinical features known to increase the risk of severe disease in 
unvaccinated populations were also associated with severe outcomes in people receiving their first dose of vaccine 
and could help inform case management and future vaccine policy formulation.
Funding UK Research and Innovation (Medical Research Council), Research and Innovation Industrial Strategy 
Challenge Fund, Scottish Government, and Health Data Research UK.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
The COVID-19 pandemic has resulted in over 220 million 
cases and 4·6 million deaths worldwide as of 
September, 2021, leading to large-scale disruption of 
societies. These figures include more than 7·2 million 
cases and almost 130 500 deaths in the UK.1 The 
emergence and subsequent spread of this novel virus has 
resulted in devastating global social and economic 
consequences, affecting nearly every aspect of our lives.2 
Although public health actions, such as lockdown 
measures, physical distancing, and improved hygiene 
practices, have reduced the likelihood of transmission, 
an urgent need for mass deployment of vaccines against 
SARS-CoV-2 remains.3
The COVID-19 vaccination programme started in 
Scotland on Dec 8, 2020, beginning with the BNT162b2 
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(Pfizer–BioNTech) COVID-19 vaccine. After approval, the 
ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccine was 
also deployed in the Scottish vaccination programme 
from Jan 4, 2021. A two-dose schedule is advised for both 
of these vaccines in the UK.4 During winter 2020–21, the 
pandemic in Scotland resulted in the highest incidence 
of SARS-CoV-2 recorded since the start of the pandemic 
in March, 2020, and until the end of May, 2021. This 
winter peak began around the first week of 
December, 2020, peaked on Jan 4, 2021, and continued to 
decline after that, which coincided with the period of 
vaccination rollout reported in this study.5
The COVID-19 vaccination programme in Scotland has 
adhered to advice from the UK Joint Committee on 
Vaccination and Immunisation (JCVI).6 The JCVI initially 
advised that, in the context of restricted vaccine supplies, 
an offer of a first dose followed by a second dose 12 weeks 
later was desirable to provide at least some protection for 
as many people as soon as possible. The JCVI prioritised 
vaccinations for those at highest risk of COVID-19 
mortality (appendix pp 1–3). Thus, the vaccine rollout 
began with care home residents, health and care workers, 
and people aged 80 years and older, followed by 
combinations of clinically vulnerable people and 
progressively younger age groups. Although this advice 
differs from trial evidence and manufacturers guidance 
on timing between doses,7–9 data from mathematical 
models suggest that this approach has the potential to 
contain the pandemic quickly, achieving optimal public 
health benefit,10 and could result in reduced cumulative 
mortality under certain conditions.11 Additionally, given 
that vaccine demand will probably exceed supply for 
some time, several countries around the world have 
either adopted the strategy of delaying provision of a 
second dose in their programmes or are considering 
doing so.12,13
Clinical trials for the licenced vaccines showed 
95% efficacy for BNT162b2 and 70% efficacy for ChAdOx1 
against symptomatic disease after two vaccine doses.7,14,15 
However, these studies might not necessarily reflect real-
world outcomes because of exclusion or under-
representation of certain populations (such as older age 
groups and those with comorbidities), differences in risk 
of infection during the observation periods, different 
criteria for diagnosis and grading the severity of infection 
between a trial and routine clinical practice, and the 
appearance of new SARS-CoV-2 variants.16,17 Analysis of 
real-world data from the vaccination programme in 
Research in context
Evidence before this study
We searched PubMed, medRxiv, and SSRN on May 27, 2021, 
for studies using free text and related MeSH terms for hospital 
admission following COVID-19 vaccination, using the terms 
“COVID-19 breakthrough infections”, “COVID-19 vaccines 
(MeSH)”, and “COVID-19 (MeSH)”. We only considered studies 
published in English. A study in Israel on 596 618 individuals 
who received the BNT162b2 (Pfizer–BioNTech) vaccine 
reported that 110 vaccinated individuals were admitted to 
hospital and there were nine deaths due to COVID-19 up to 
42 days after vaccination. However, nearly all individuals (96%) 
in the study received a second dose of vaccination (95% of 
participants received the second dose before day 24). Public 
Health England reported that 9% of people aged 80 years or 
older who tested positive for COVID-19 after a first dose of 
BNT162b2 vaccine and 7% of people who received a first dose 
of the ChAdOx1 (Oxford–AstraZeneca) vaccine were 
subsequently admitted to hospital for COVID-19. A preprint 
study in northwest London followed up 389 587 people for an 
average of 29 days after the first dose of vaccine, with 
288 patients admitted to hospital (155 in the first 14 days after 
vaccination). A separate report of the ISARIC/CO-CIN study in 
the UK reported that, since the start of the vaccination 
programme, one in 25 people admitted to hospital for 
COVID-19 had received at least one vaccine dose. Of the 
42 788 people recruited to this study since Dec 8, 2020, 
4·2% had been vaccinated (1685 with one dose and 27 with 
two doses), with a median time from vaccination to admission 
to hospital of 10 days.
Added value of this study
This national-level analysis found that at 14 days or longer 
since the first vaccine dose, there were 883 COVID-19 
admissions to hospital and 541 deaths in almost 2·57 million 
individuals in Scotland. Older age, increasing number of 
underlying comorbidities, recent admission to hospital, being 
in a high-risk occupation, being a care home resident, being 
male, being socioeconomically deprived, and being an 
ex-smoker were all associated with an increased risk of severe 
post-vaccine COVID-19 events. By contrast, previous 
COVID-19 infection had a protective effect.
Implications of all the available evidence
The rollout of the COVID-19 vaccination programme was 
associated with low numbers of post-vaccination serious 
COVID-19 outcomes at 14 days or longer since vaccination. 
Whether the same degree of protection is maintained beyond 
the analysed period of follow-up and once lockdown 
measures are lifted remains to be seen. As the rollout of 
vaccination programmes continues worldwide, there is a 
need to identify those at increased risk of breakthrough 
infections and identify mechanisms to reduce those risks. 
The benefits of an expedited second dose compared with a 
longer gap between vaccinations are unclear, as there is 
potential longer-term gain from an enhanced immune 
response with a longer interval between the doses.
See Online for appendix
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Scotland between Dec 8, 2020, and Feb 22, 2021, found 
that the first dose of the mass vaccination programme 
was associated with a 91% (95% CI 85–94) reduction in 
COVID-19 admissions to hospital for the BNT162b2 
vaccine and an 88% (75–94) reduction for ChAdOx1 at 
28–34 days post-vaccination.18
Even with highly effective vaccines, some vaccinated 
individuals will still become infected with SARS-CoV-2 
and develop severe COVID-19.19 It is important to 
understand the frequency of such severe COVID-19 
outcomes and identify who is at the greatest risk to 
inform clinical practice, public health strategy, and 
evolving vaccination policy. We sought to estimate the 
frequency of COVID-19 admissions to hospital or deaths 
14 days or more after receiving the first vaccine dose and 
to characterise individuals with these outcomes in terms 
of demographic and clinical considerations.
Methods 
Study design and population 
The Early Pandemic Evaluation and Enhanced 
Surveillance of COVID-19 (EAVE II) platform is an open, 
real-time, prospective observational cohort with national-
level coverage in Scotland that uses linked vaccination, 
primary care, laboratory testing, hospitalisation, and 
mortality data, and has been described in detail 
elsewhere.20 Data were available for 5·4 million people in 
Scotland (around 99% of the population) within the 
EAVE II platform. The population of interest was all 
adults (aged ≥18 years on Dec 8, 2020) who received the 
first dose of either the BNT162b2 vaccine or the ChAdOx1 
vaccine by April 18, 2021, and who did not have a 
COVID-19 hospitalisation or any death less than 14 days 
after vaccination. Events less than 14 days after 
vaccination were excluded to allow time for an immune 
response to develop and to avoid inclusion of any 
infections acquired before vaccination.21
Data on all individuals from 940 general practices 
across Scotland were deterministically linked to data 
on SARS-CoV-2 testing, the vaccination programme, 
hospital admissions, and mortality records using the 
Community Health Index number, which is a unique 
identifier used in all health-care contacts across Scotland. 
Data were available for each individual from general 
practice (GP) records, the Electronic Communication 
of Surveillance in Scotland (ECOSS) for laboratory 
data, vaccination data from GP records and the Turas 
Vaccination Management Tool (TVMT),22 the Scottish 
Morbidity Record database and Rapid Preliminary 
Inpatient Data for hospital admission data,23 and 
National Records of Scotland death registry for mortality 
data. Laboratory data from ECOSS included all RT-PCR 
test results from both UK National Health Service (NHS) 
laboratories (pillar 1) and Lighthouse Government 
laboratories (pillar 2).24 Vaccination information was 
available on individuals vaccinated in general practices 
directly from GP records. Information on those vacci-
nated in community vaccination hubs and any other 
settings, such as care homes and hospitals, was obtained 
from the national TVMT database.22
Our population of interest included individuals for 
whom 14 days or more had passed after receiving a first 
dose of vaccine between Dec 8, 2020, and April 18, 2021, 
until admission to hospital for COVID-19, death due to 
COVID-19, or the end of the study on April 18, 2021. 
Vaccinated groups were stratified by time intervals for 
14–20 days, 21–27 days, 28–34 days, 35–41 days, and 42 or 
more days post-vaccination, and by the type of vaccine 
received.
Ethical approval was granted by the National Research 
Ethics Service Committee, Southeast Scotland 02 
(reference number 12/SS/0201). Approval for data 
linkage and its use was granted by the Public Benefit and 
Privacy Panel for Health and Social Care (reference 
number 1920-0279) and hence individual written patient 
consent was not required.
Outcomes 
We identified COVID-19 hospital admissions that 
occurred between Dec 22, 2020 (14 days after the 
vaccination programme started), and April 18, 2021. 
Cases were defined as an individual admitted to hospital 
with COVID-19 as the recorded cause of admission, 
those with any hospital admissions within 14 days of a 
positive RT-PCR test for SARS-CoV-2 infection, or those 
with any admission to hospital for a non-COVID-19 
reason and with a positive RT-PCR test for SARS-CoV-2 
infection during that admission (appendix p 4).
We defined COVID-19 deaths as any individual with 
COVID-19 as the main International Classification of 
Diseases (ICD)-10 cause of death recorded on the death 
certificate, or death from any cause within 28 days of 
a positive RT-PCR test for SARS-CoV-2 infection 
(appendix p 4).1
Figure 1: Flow chart representing vaccine coverage in Scotland between 
Dec 8, 2020, and April 18, 2021, including severe outcomes due to COVID-19 
14 days or more after first vaccine dose
313 patients died without being admitted to hospital.
883 admitted to hospital
1196 had a severe COVID-19 outcome ≥14 days after vaccination
2 572 008 included in vaccinated cohort
2 572 655 individuals vaccinated between Dec 8, 2020, and April 18, 2021
647 had a severe event within
the first 14 days of
vaccination
541 died (228 first admitted to
hospital)
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Population characteristics and covariates 
We identified characteristics of interest at baseline for 
the study population on Dec 8, 2020, namely age, sex, 
socioeconomic status measured by quintiles of the 
Scottish Index of Multiple Deprivation (SIMD), residential 
settlement measured by the urban rural six-fold 
classification, health board of residence, COVID-19 before 
vaccination, smoking status, the number and types 
of comorbidities commonly associated with severe 
COVID-19 illness, and calendar week of vaccination. We 
identified people living in households of more than ten 
people where the average age of residents was 65 years or 
older and used this as a proxy for living in a residential 
care home.
SIMD was allocated based on an individual’s home 
postcode, with quintiles of population ranging from 1 for 
the most deprived 20% to 5 for the least deprived 20% of 
the population. Residential settlement is a measure of 
rurality that ranges from 1 for large urban areas to 6 for 
small remote rural areas. Comorbidities of interest 
included a history of asthma, chronic kidney disease, 
liver cirrhosis, chronic neurological condition, heart 
failure, diabetes (type 1 and type 2), dementia, or coronary 
heart disease, since these have been shown to be 
associated with poorer COVID-19 outcomes.25 Smoking 
status (never smoker, current smoker, or ex-smoker), 
blood pressure (normal, low, high, very high, no 
investigation, and unknown), and body-mass index 




outcome, n (rate 
per 1000 person-
years)
Overall ·· 1196 (4·6)
Sex
Female 1 418 305 (55·1%) 681 (4·5)
Male 1 153 703 (44·9%) 515 (4·7)
Age, years
18–64 1 659 660 (64·5%) 235 (1·9)
65–79 697 505 (27·1%) 327 (3·3)
≥80 214 843 (8·4%) 634 (18·6)
Previous history of COVID-19
No 2 488 274 (96·7%) 1154 (4·6)
Yes 83 734 (3·3%) 42 (5·4)
Previous history of hospitalisation*
No 2 511 281 (97·6%) 1068 (4·2)
Yes 60 727 (2·4%) 128 (20·4)
Residential care home
No 2 552 805 (99·3%) 936 (3·6)
Yes 19 203 (0·7%) 260 (96·5)
Deprivation status
1—Most deprived 468 835 (18·2%) 328 (6·9)
2 504 810 (19·6%) 285 (5·5)
3 526 056 (20·5%) 194 (3·6)
4 537 664 (20·9%) 195 (3·6)
5—Least deprived 521 213 (20·3%) 181 (3·5)
Unknown 13 430 (0·5%) 13 (10·2)
Urban rural score
1—Large urban area 776 050 (30·3%) 365 (4·7)
2 990 996 (38·7%) 497 (4·9)
3 258 023 (10·1%) 119 (4·5)
4 138 885 (5·4%) 52 (3·6)
5 248 218 (9·7%) 124 (5·0)
6—Remote rural area 146 406 (5·7%) 26 (1·8)
Unknown 13 430 (0·5%) 13 (10·2)
Smoking status
Ex-smoker 432 792 (16·8%) 312 (6·3)
Non-smoker 999 523 (38·9%) 391 (3·9)
Smoker 621 559 (24·2%) 301 (4·7)
Unknown 518 134 (20·1%) 192 (4·2)




outcome, n (rate 
per 1000 person-
years)
(Continued from previous column)
Number of comorbidities†
0 1 233 224 (47·9%) 177 (1·6)
1 760 243 (29·6%) 207 (2·7)
2 337 957 (13·1%) 258 (6·4)
3 141 200 (5·5%) 236 (12·7)
4 60 156 (2·3%) 138 (16·5)
≥5 39 228 (1·5%) 180 (32·1)
Number of previous COVID-19 tests‡
0 2 059 613 (80·1%) 524 (2·6)
1 313 028 (12·2%) 128 (5·8)
2 78 230 (3·0%) 110 (12·6)
3 29 412 (1·1%) 101 (28·2)
4–9 47 448 (1·8%) 208 (32·9)
≥10 44 277 (1·7%) 71 (11·6)
Medical history
Asthma 352 672 (13·7%) 169 (4·7)
Chronic kidney disease 
(stages 3–5)
151 969 (5·9%) 318 (14·4)
Liver cirrhosis 20 301 (0·8%) 16 (6·8)
Chronic neurological 
condition
16 897 (0·7%) 9 (4·7)
Heart failure 44 663 (1·7%) 94 (15·1)
Type 1 diabetes 20 325 (0·8%) 8 (3·8)
Type 2 diabetes 243 918 (9·5%) 288 (9·3)
Dementia 34 552 (1·3%) 259 (51·8)
Coronary heart disease 190 015 (7·4%) 278 (10·7)
Data are n (%), unless otherwise indicated. Percentages might not sum to 100 
because of rounding. *Previous history of hospitalisation status defined as admission 
to hospital within 4 weeks before the first vaccination. †Individual QCOVID risk 
groups found in the appendix (pp 21–22). ‡A proxy for high-risk occupations.
Table 1: Characteristics of individuals in Scotland with any first 
vaccination and COVID-19 hospitalisations or deaths (severe COVID-19 
outcome) 14 days or more after vaccination
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analysis. The number of previous SARS-CoV-2 tests (a 
proxy for high-risk occupational groups who were 
repeatedly tested) and previously testing positive were 
retrieved from laboratory testing data. We also identified 
people who had been admitted to hospital in the 4 weeks 
before their first vaccination.
Statistical analysis 
We summarised the characteristics of individuals with 
severe COVID-19 outcomes of interest (ie, admitted to 
hospital or died due to COVID-19 illness) 14 days or more 
after the first dose of vaccine overall and by each vaccine 
type. Baseline characteristics of the study population 
were reported for demographic and clinical characteristics 
of interest using counts and proportions. These factors 
were also reported by the type of vaccine used and by 
those who subsequently were admitted to hospital or 
died because of COVID-19 at least 14 days after 
vaccination. For people with an event of interest, we 
calculated the absolute risk per 1000 person-years for 
each factor based on the total follow-up of individuals 
within each group of interest.
We used generalised linear models assuming a 
Poisson distribution with person-time for an offset 
representing the time at risk to derive rate ratios (RRs) 
with 95% CIs for admission to hospital or death from 
COVID-19. We calculated both the unadjusted and 
adjusted RRs for all predictors including age, sex, 
previous history of COVID-19, SIMD, urban rural 
classification, number of risk groups, care home 
residence, the number of previous SARS-CoV-2 tests (a 
proxy for high-risk occupational groups), smoking 
status, previous history of hospitalisation (admission to 
hospital within 4 weeks before vaccination), and time 
since first vacci nation. RRs for individual comorbidities 
were adjusted for age, sex, and SIMD in a separate 
model for each condition. Calendar time intervals by 
week and registered health board were also included as 
confounders to account for the evolving state of the 
pandemic over time and by region. A count of 
conditions was included in our final adjusted model 
rather than individual conditions due to multi-
collinearity between these factors. Survival analysis that 
took into account the time at risk was used to derive 
cumulative incidence plots for occurrence of admission 
to hospital or death due to COVID-19. All statistical 
tests were two-tailed with a 5% significance level. R 
(version 3.5.1) was used to carry out all statistical 
analyses, which were performed by one statistician 
(UA) and subsequently independently checked by a 
second statistician (CR or EM).
A statistical analysis plan was developed before 
undertaking the analysis and published on the EAVE II 
project website.26 RECORD27 and STROBE28 were used to 
guide transparent reporting (appendix pp 5–9). Our 
analysis code will be made publicly available at the time 
of publication.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
Between Dec 8, 2020, and April 18, 2021, 2 570 812 
(>99·9%) of 2 572 008 individuals aged 18 years and older 
who were administered a first dose of COVID-19 vaccine 
















recipients, n (rate 
per 1000 person-
years)
Overall ·· 593 (5·3) ·· 603 (4·1)
Sex
Female 525 708 (62·5%) 353 (4·9) 892 597 (51·6%) 328 (4·2)
Male 315 382 (37·5%) 240 (5·8) 838 321 (48·4%) 275 (4·0)
Age, years
18–64 476 007 (56·6%) 107 (1·8) 1 183 653 (68·4%) 128 (1·9)
65–79 328 733 (39·1%) 158 (3·3) 368 772 (21·3%) 169 (3·3)
≥80 36 350 (4·3%) 328 (62·8) 178 493 (10·3%) 306 (10·6)
Previous history of COVID-19
No 807 322 (96·0%) 562 (5·2) 1 680 952 (97·1%) 592 (4·1)
Yes 33 768 (4·0%) 31 (7·0) 49 966 (2·9%) 11 (3·3)
Previous history of hospitalisation*
No 828 156 (98·5%) 552 (5·0) 1 683 125 (97·2%) 516 (3·6)
Yes 12 934 (1·5%) 41 (25·2) 47 793 (2·8%) 87 (18·7)
Residential care home
No 822 585 (97·8%) 336 (3·0) 1 730 220 (>99·9%) 600 (4·1)
Yes 18 505 (2·2%) 257 (98·3) 698 (<0·1%) 3 (37·3)
Deprivation status
1—Most deprived 155 179 (18·4%) 142 (6·8) 313 656 (18·1%) 186 (7·0)
2 166 798 (19·8%) 131 (5·8) 338 012 (19·5%) 154 (5·3)
3 168 335 (20·0%) 115 (5·2) 357 721 (20·7%) 79 (2·5)
4 178 334 (21·2%) 105 (4·4) 359 330 (20·8%) 90 (3·0)
5—Least deprived 167 512 (19·9%) 88 (3·8) 353 701 (20·4%) 93 (3·2)
Unknown 4932 (0·6%) 12 (18·8) 8498 (0·5%) 1 (1·6)
Urban rural score
1—Large urban area 250 598 (30·0%) 160 (4·7) 525 452 (30·5%) 205 (4·7)
2 340 101 (40·7%) 240 (5·2) 650 895 (37·8%) 257 (4·7)
3 81 977 (9·8%) 53 (4·9) 176 046 (10·2%) 66 (4·3)
4 42 682 (5·1%) 33 (6·0) 96 203 (5·6%) 99 (2·1)
5 72 339 (8·7%) 80 (8·3) 175 879 (10·2%) 44 (2·9)
6—Remote rural 
area
48 461 (5·8%) 15 (2·5) 97 945 (5·7%) 11 (1·2)
Unknown 4932 (0·6%) 12 (18·8) 8498 (0·5%) 1 (1·6)
Smoking status
Ex-smoker 139 457 (16·6%) 139 (7·2) 293 335 (16·9%) 173 (5·6)
Non-smoker 333 702 (39·7%) 189 (4·2) 665 821 (38·5%) 202 (3·6)
Smoker 194 897 (23·2%) 129 (4·9) 426 662 (24·6%) 172 (4·6)
Unknown 173 034 (20·6%) 136 (6·0) 345 100 (19·9%) 56 (2·4)
(Table 2 continues on next page)
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14 days after vaccination and so were eligible for inclusion 
in the study (figure 1; appendix pp 10–14). Eligible 
individuals were followed up for 391 571 person-years 
until any admission to hospital for COVID-19 illness, 
COVID-19 death, or the end of follow-up on April 18, 2021 
(table 1). The median follow-up after first vaccination was 
55 days (IQR 31–67). The range of follow-up after first and 
second doses of vaccine was to a maximum of 128 days.
841 090 (32·7%) individuals received a first dose of 
BNT162b2 and 1 730 918 (67·3%) individuals received a 
first dose of ChAdOx1 vaccine (table 2). 694 915 (27·0%) 
individuals received a second vaccine dose within the 
study period. 412 649 (59·4%) individuals received a 
second dose of BNT162b2 and 282 266 (40·6%) 
individuals received a second dose of ChAdOx1 with a 
combined 43 166 years of follow-up after the second dose. 
The median follow-up after the second dose was 19 days 
(IQR 8–33).
1196 (<0·1%) individuals (4·6 events per 1000 person-
years) had the outcome of interest (table 1). 883 individuals 
were admitted to hospital and 541 people died with 
COVID-19 14 days or more after the first vaccination, 
228 of whom died after hospitalisation (figure 1). There 
were 39 deaths and hospitalisations among individuals 
who received a second vaccine dose, which translated 
into an event rate of 0·9 per 1000 person-years. Among 
individuals who received BNT162b2 and ChAdOx1 
vaccines, there were 593 (5·3 events per 1000 person-
years) and 603 (4·1 events per 1000 person-years) events 
of interest, respectively (table 2). The rate of events 
differed for the two vaccines most notably in those aged 
80 years and older, with people receiving BNT162b2 
having a rate of 62·8 events per 1000 person-years 
compared with a rate of 10·6 per 1000 person-years 
for ChAdOx1.
We recorded the distribution of hospitalisations due to 
COVID-19, deaths due to COVID-19 and these events 
together in the Scottish population over winter 2020/21 
when the study was conducted (figure 2). We also 
generated the same outcomes stratified by age and vaccine 
type among vaccinated individuals (appendix pp 23–28).
We reported adjusted RRs for demographic and clinical 
characteristics and associations with severe COVID-19 
outcomes (table 3; unadjusted RRs are shown in the 
appendix pp 15–17). When con sidering adjusted data for 
both vaccines combined, older age, higher number of 
comorbidities, hospitalisation in the previous 4 weeks 
before vaccination, having a high-risk occupation, 
residing in a care home, living in areas with the highest 
deprivation, being male, and being an ex-smoker 
increased the risk of hospitalisation or death from 
COVID-19 (table 3). Previous history of COVID-19 was 
protective against severe COVID-19 outcomes (table 3).
For BNT162b2, older age, increasing number of 
comorbidities, living in a care home, having a high-risk 
occupation, being in the most socially deprived 
classification, recent admission to hospital, being an 
ex-smoker, and living in a more rural location were all 
associated with an increased risk of severe COVID-19 
outcomes, whereas previous history of COVID-19 was 
associated with a reduced risk (table 3). For ChAdOx1, 
older age, increasing number of comorbidities, having a 
high-risk occupation, being in the most socially deprived 
classification, and recent admission to hospital were 
associated with an increased risk of severe COVID-19 
outcomes, whereas previous history of COVID-19 was 
associated with a reduced risk (table 3).
The 14–20-day period after vaccination had a greater 
risk of severe COVID-19 outcomes than later periods for 
the vaccines combined and individually. People who 
were vaccinated with a history of asthma, chronic kidney 
condition, heart failure, type 2 diabetes, dementia, 
















recipients, n (rate 
per 1000 person-
years)
(Continued from previous page)
Number of comorbidities†
0 420 033 (49·9%) 82 (1·5) 813 191 (47·0%) 95 (1·8)
1 244 230 (29·0%) 85 (2·6) 516 013 (29·8%) 122 (2·7)
2 103 811 (12·3%) 124 (8·8) 234 146 (13·5%) 134 (5·2)
3 42 751 (5·1%) 124 (20·9) 98 449 (5·7%) 112 (8·9)
4 18 212 (2·2%) 76 (29·8) 41 944 (2·4%) 62 (10·7)
≥5 12 053 (1·4%) 102 (59·9) 27 175 (1·6%) 78 (19·9)
Number of previous COVID-19 tests‡
0 612 187 (72·8%) 151 (1·9) 1 447 426 (83·6%) 373 (3·0)
1 114 362 (13·6%) 87 (5·6) 198 666 (11·5%) 95 (6·0)
2 33 236 (4·0%) 67 (14·7) 44 994 (2·6%) 43 (10·4)
3 14 665 (1·7%) 82 (40·6) 14 747 (0·9%) 19 (12·1)
4–9 29 236 (3·5%) 154 (37·2) 18 212 (1·1%) 54 (24·8)
≥10 37 404 (4·4%) 52 (9·7) 6873 (0·4%) 19 (25·8)
Medical history
Asthma 110 799 (13·2%) 57 (5·3%) 241 873 (14·0%) 112 (3·9)
Chronic kidney 
disease (stages 3–5)
44 133 (5·2%) 142 (11·1%) 107 836 (6·2%) 176 (22·6)




4567 (0·5%) 6 (2·3%) 12 330 (0·7%) 3 (10·0)
Heart failure 12 283 (1·5%) 31 (14·0) 32 380 (1·9%) 63 (18·0)
Diabetes (type 1) 5582 (0·7%) 4 (2·9) 14 743 (0·9%) 4 (5·6)
Diabetes (type 2) 79 611 (9·5%) 129 (7·9) 164 307 (9·5%) 159 (11·8)
Dementia 17 274 (2·1%) 225 (13·2) 17 278 (1·0%) 34 (92·6)
Coronary heart 
disease
60 379 (7·2%) 120 (9·0) 129 636 (7·5%) 158 (14·2)
Data are n (%), unless otherwise indicated. Percentages might not sum to 100 because of rounding. *Previous history 
of hospitalisation status defined as admission to hospital within 4 weeks before first dose of vaccine. †Individual 
QCOVID risk groups found in the appendix (pp 21–22). ‡A proxy for high-risk occupations.
Table 2: Characteristics of individuals in Scotland and number and rate of severe COVID-19 outcomes 
14 days or more after first dose of vaccine
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of admission to hospital or death due to COVID-19 
after adjusting for age, sex, and SIMD (table 4). When 
considering people vaccinated with BNT162b2 separately, 
we found no association between asthma or heart failure 
and an increased risk of adverse COVID-19 outcomes. 
We reported cumulative incidence plots for admission to 
hospital or death due to COVID-19 for vaccine types, age 
groups, number of risk groups, and socioeconomic 
status (appendix pp 29–33). We did a sensitivity analysis 
restricting our case definition to those with a confirmed 
diagnosis of COVID-19 (ICD code U07.1) or with a 
positive RT-PCR test, which showed similar results 
(appendix pp 18–20).
Discussion 
We found a low risk of COVID-19 hospitalisations or 
deaths 14 days or more after the first vaccination dose, 
with less than 0·05% of individuals receiving at least 
one vaccination having a subsequent breakthrough 
event. Older people, those with underlying long-term 
conditions, those with a recent hospital admission before 
vaccination, those with a high-risk occupation, care 
home residents, men, those with high socioeconomic 
deprivation, and ex-smokers had a greater risk of 
COVID-19 hospitalisation or death. With the exception 
of being an ex-smoker, these factors are known to be 
associated with an increased risk of severe COVID-19 
in the unvaccinated population.25 By contrast, previous 
COVID-19 was associated with a reduced risk of a serious 
COVID-19 outcome after the first vaccine dose.
The rate of hospitalisation or death for COVID-19 
related illness during the study period was 4·6 events 
per 1000 person-years (1196 events in total). Over the 
same period, we calculated the rate of hospitalisation or 
death from COVID-19 as 8·57 events per 1000 person-
years (10 282 events in total) in the unvaccinated 
population in Scotland, despite the fact that this 
unvaccinated group was a much younger population who 
the JCVI had assessed to be at a substantially lower risk 
of severe COVID-19 outcomes.29
We excluded events that occurred less than 14 days 
after vaccination to allow time for the vaccine to trigger 
an immune response; it is unclear whether the available 
vaccines confer protection during this initial two week 
period.30,31 Some severe COVID-19 events seen in the 
initial period after vaccination might also have occurred 
in those with infection before vaccination.19,31 The rate of 
events during this period was 6·73 per 1000 person-years.
Previous studies have reported impressive vaccine 
effectiveness in preventing severe outcomes due to 
COVID-19 after one or two doses, with only 110 admissions 
to hospital and nine deaths 6 weeks after administration 
of the first dose of vaccine in almost 600 000 people in 
Israel.32 However, it has become clear that the available 
vaccines do not prevent 100% of infections and a 
proportion of those infected will progress to have severe 
COVID-19 outcomes.19 The factors identified as being 
associated with poorer outcomes in this analysis are 
largely similar to those reported as risk factors for serious 
COVID-19 outcomes in unvaccinated populations.33 Our 
finding of poorer outcomes associated with increasing 
numbers of comorbidities is in keeping with findings 
from a study in Israel, which suggested that vaccine 
effectiveness might be slightly lower among people with 
higher numbers of coexisting conditions.32 Similarly, 
evidence from Public Health England that history of 
Figure 2: Severe COVID-19 outcomes in Scotland in winter 2020–21 for hospitalisation (A), deaths (B), and 
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COVID-19 illness increases vaccine response is supported 
by the reduction in risk of severe COVID-19 outcomes for 
those with history of the disease seen in this study.34 Other 
work in the USA and Italy has shown that a single mRNA 
vaccine dose (BNT162b2 or mRNA-1273 [Moderna]) in 
people with previous COVID-19 elicited similar immune 
responses to two vaccine doses in patients with no 
previous history.35–37
To our knowledge, this is the first national study to 
estimate and characterise the risk of severe COVID-19 
events after the first vaccine dose and the study has 
several key strengths. First, we used a national platform 
of relevant linked data based on the Scottish Government’s 
mandated reporting from all NHS providers delivering 
rapid access to and analysis of data on vaccination status 
and clinical outcomes from routinely collected electronic 
health records.18,20 Second, the study is population-based, 
and thus has fewer biases than studies based on selected 
samples of the population. Third, almost 2·57 million 
Both vaccines BNT162b2 ChAdOx1
Time since first vaccination, days
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Data are adjusted (for age, sex, previous history of COVID-19, Scottish Index of 
Multiple Deprivation, urban–rural classification, number of risk groups, care home 
residence, number of previous COVID-19 tests [a proxy for high-risk occupational 
groups], smoking status, previous history of hospitalisation [admission to 
hospital within 4 weeks before vaccination], and time since first vaccination) 
RR (95% CI). RR=rate ratio. *Previous history of hospitalisation status defined as 
admission to hospital within 4 weeks before first dose of vaccine. †Individual 
QCOVID risk groups found in the appendix (pp 21–22).
Table 3: Associations for multivariate Poisson models for demographic 
and clinical characteristics of patients with hospitalisations or death 
due to COVID-19 14 days or more after first vaccine dose
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people were included in the analysis, meaning the study 
was well powered to assess the outcomes of interest 
overall and by individual vaccine. Therefore, our findings 
are likely to be relevant across the UK and other countries 
that are running vaccination programmes using the same 
vaccines.
A limitation of this study is that we were unable to 
report on risk of SARS-CoV-2 infection and less severe 
COVID-19 outcomes. We were limited in this respect by 
insufficient systematic testing for presence of COVID-19 
in the population of those who were vaccinated. We were 
also unable to make robust comparisons between the 
vaccines because of differential use of the two deployed 
vaccines during the study period. From Dec 8, 2020, the 
first UK-approved vaccine BNT162b2 was targeted 
towards care home residents, nursing staff, social carers, 
and frontline health and social care workers. From 
Jan 4, 2021, onwards, ChAdOx1 became available and 
was deployed for all prioritised groups, particularly in 
community settings, because of less onerous storage 
requirements. During winter 2020–21 the highest 
incidence in Scotland of SARS-CoV-2 infection at any 
time during the pandemic was recorded; this began 
around the first week of December, 2020, peaked on 
Jan 4, 2021, and continued its decline after that. As 
vaccine rollouts were started at different times, there 
were also different background levels of infection for 
vaccine recipients. We used relatively broad criteria to 
identify COVID-19 admission and so might have 
included people who were admitted to hospital or died 
with COVID-19 but not directly because of it. We 
performed a sensitivity analysis restricting our case 
definition to those with a confirmed diagnosis of 
COVID-19 (ICD code U07.1) or with a positive RT-PCR 
test. This analysis showed very similar results (appendix 
pp 18–20). We also examined death records and 
516 (95%) of the reported deaths had a confirmed 
diagnosis of COVID-19 as the main or a contributory 
cause of death. Although there was no national direction 
of changes in COVID-19 hospital admission policy over 
the relatively short duration of this study, there remains 
the possibility that some of these admissions to hospital 
were due to a change in admission threshold for 
COVID-19.
The UK vaccination programme decision to delay 
administration of second doses to 8–12 weeks rather 
than the shorter 3-week schedule used in the trials7,15 
was not based on efficacy data, but rather on trying to 
maximise coverage with a first dose as quickly as 
possible.6,38 The initial focus was on individuals at 
highest risk and frontline NHS and care home workers. 
Our data showing benefit from a single dose and among 
those at most risk of serious complications is therefore 
particularly valuable. Other work has also suggested 
that a longer interval between doses might ultimately 
trigger a stronger immune response, but this is still an 
area of uncertainty.39–41 Monitoring the number of 
COVID-19-related serious outcomes in the vaccinated 
population between vaccine doses is important to enable 
evaluation of the effectiveness of the mass vaccination 
programme. Such information can help inform future 
decisions on vaccine schedules, both within the UK and 
internationally. The use of robust epidemiological 
studies using routinely collected observational data is 
vital in assessing real-life effects of the COVID-19 
vaccines and vaccination programme. Our analysis was 
performed during a period where there was a high 
background incidence of SARS-CoV-2 infection and a 
national lockdown in place in Scotland (and across the 
UK), so these findings must be interpreted within this 
context. We plan to continue analysis as the UK relaxes 
lockdown restrictions, extends the vaccination 
programme to younger and healthier individuals, and 
introduces Moderna and other vaccines into its national 
vaccination programme.
In conclusion, our findings from this national 
evaluation of first dose mass vaccination rollout across 
Scotland found a small risk of hospitalisation or death 
due to COVID-19 illness 14 days or more days after the 
first vaccine dose, with older people, those with greater 
numbers of long-term conditions, people admitted to 
hospital in the recent weeks before their vaccination, 
people in high-risk occupations, care home residents, 
those from deprived backgrounds, men, and ex-smokers 
at the highest risk. By contrast, previous infection with 
COVID-19 was associated with a reduced risk of these 
events following vaccination. Overall, the rate of severe 
COVID-19 outcomes for individuals from 14 days onwards 
after a first dose of ChAdOx1 or BNT162b2 was very low, 
with less than 0·05% of people who received at least 
one vaccine suffering an adverse breakthrough event.
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